Protein Structure Facilitates High-Resolution Immunological Mapping.

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-12-05 Print Date: 2017-12-01 DOI:10.1128/CVI.00275-17

Madison Zuverink, Joseph T Barbieri

引用次数: 1

Abstract

Select agents (SA) pose unique challenges for licensing vaccines and therapies. In the case of toxin-mediated diseases, HHS assigns guidelines for SA use, oversees vaccine and therapy development, and approves animal models and approaches to identify mechanisms for toxin neutralization. In this commentary, we discuss next-generation vaccines and therapies against ricin toxin and botulinum toxin, which are regulated SA toxins that utilize structure-based approaches for countermeasures to guide rapid response to future biothreats.

Abstract Image

查看原文本刊更多论文

蛋白质结构促进高分辨率免疫制图。

选择制剂(SA)对疫苗和疗法的许可提出了独特的挑战。在毒素介导性疾病的情况下，卫生与公众服务部为SA的使用制定指导方针，监督疫苗和治疗方法的开发，并批准动物模型和方法，以确定毒素中和机制。在这篇评论中，我们讨论了针对蓖麻毒素和肉毒杆菌毒素的下一代疫苗和治疗方法，这两种毒素是受调节的SA毒素，利用基于结构的对策方法来指导对未来生物威胁的快速反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.